Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 55INDUSTRY 26NIH 13OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Somatostatinoma 1Carcinoma, Neuroendocrine 1

Interventions

Specimen Handling 47Magnetic Resonance Spectroscopy 38Cyclophosphamide 28Vincristine 22Radiation 19Dexamethasone 19Etoposide 18Cisplatin 18Carboplatin 17Biopsy 17Radiotherapy 16Doxorubicin 13Cytarabine 13daratumumab 12Leucovorin 12Methotrexate 11Gemcitabine 11X-Rays 10Standard of Care 10Platinum 10Docetaxel 10durvalumab 9Rituximab 9Radiotherapy, Intensity-Modulated 9Prednisone 9Practice Guidelines as Topic 9Calcium Dobesilate 91,2-diaminocyclohexaneplatinum II citrate 9merphos 8dexamethasone acetate 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Temozolomide × 90 days × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡